Just months ago, a Phase-2 clinical trial of a monoclonal antibody, gosuranemab, against extracellular N-terminal fragments of tau (eTau) in patients with MCI or mild Alzheimer’s disease failed on all clinical endpoints even though it reduced CSF levels of the target (Carroll 2021; see Web Resources). Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.